Matrikine and matricellular regulators of EGF receptor signaling on cancer cell migration and invasion

Laboratory Investigation

Volumn 94, Issue 1, 2014, Pages 31-40

  Grahovac, Jelena ^a   Wells, Alan ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

amoeboid; cancer invasion; decorin; EGFR; mesenchymal; migration; tenascin C

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FIBULIN; KALININ; OSTEONECTIN; OSTEOPONTIN; TENASCIN; THROMBOSPONDIN;

ARTICLE; CANCER CELL; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL STRUCTURE; CELL SURFACE; CYTOSKELETON; EXTRACELLULAR MATRIX; METASTASIS; NERVE CELL PLASTICITY; PRIORITY JOURNAL; PROTEIN BINDING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR INVASION;

CELL MOVEMENT; EXTRACELLULAR MATRIX PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM INVASIVENESS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84891546458     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2013.132     Document Type: Article

References (156)

1. Naba A, Clauser KR, Hoersch S, et al. The matrisome: In silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics 2012;11:M111 014647
2. Wong GS, Rustgi AK. Matricellular proteins: Priming the tumour microenvironment for cancer development and metastasis. Br J Cancer 2013;108:755-761
3. Chong HC, Tan CK, Huang RL, et al. Matricellular proteins: A sticky affair with cancers. J Oncol 2012;2012:351089
4. Wells A. EGF receptor. Int J Biochem Cell Biol 1999;31:637-643
5. Wells A. Tumor invasion: Role of growth factor-induced cell motility. Adv Cancer Res 2000;78:31-101
6. Wells A, Grahova J, Wheeler S, et al. Targeting tumor cell motility as a strategy against invasion and metastasis. Trends Pharmacol Sci 2013;34:283-289
7. Condeelis JS, Wyckoff JB, Bailly M, et al. Lamellipodia in invasion. Semin Cancer Biol 2001;11:119-128
8. Swindle CS, Tran KT, Johnson TD, et al. Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J Cell Biol 2001;154:459-468
9. Schenk S, Hintermann E, Bilban M, et al. Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution. J Cell Biol 2003;161:197-209
10. Iyer AK, Tran KT, Borysenko CW, et al. Tenascin cytotactin epidermal growth factor-like repeat binds epidermal growth factor receptor with low affinity. J Cell Physiol 2007;211:748-758
11. Iyer AK, Tran KT, Griffith L, et al. Cell surface restriction of EGFR by a tenascin cytotactin-encoded EGF-like repeat is preferential for motility-related signaling. J Cell Physiol 2008;214:504-512
12. Fan VH, Tamama K, Au A, et al. Tethered epidermal growth factor provides a survival advantage to mesenchymal stem cells. Stem Cells 2007;25:1241-1251
13. Rodrigues M, Blair H, Stockdale L, et al. Surface tethered epidermal growth factor protects proliferating and differentiating multipotential stromal cells from FasL-induced apoptosis. Stem Cells 2013; 31:104-116
14. Anderson AR, Weaver AM, Cummings PT, et al. Tumor morphology and phenotype evolution driven by selective pressure from the microenvironment. Cell 2006;127:905-915
15. Grahovac J, Becker D, Wells A. Melanoma Cell Invasiveness Is Promoted at Least in Part by the Epidermal Growth Factor-Like Repeats of Tenascin-C. J Invest Dermatol 2012;133:210-220
16. Neill T, Schaefer L, Iozzo RV. Decorin: A guardian from the matrix. Am J Pathol 2012;181:380-387
17. Sahai E, Marshall CJ. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol 2003;5:711-719
18. Wolf K, Mazo I, Leung H, et al. Compensation mechanism in tumor cell migration: Mesenchymal-Amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 2003;160:267-277
19. Friedl P, Wolf K. Plasticity of cell migration: A multiscale tuning model. J Cell Biol 2010;188:11-19
20. Wolf K, Friedl P. Extracellular matrix determinants of proteolytic and non-proteolytic cell migration. Trends Cell Biol 2011;21:736-744
21. Friedl P. Prespecification and plasticity: Shifting mechanisms of cell migration. Curr Opin Cell Biol 2004;16:14-23
22. Wyckoff JB, Pinner SE, Gschmeissner S, et al. ROCK- and myosindependent matrix deformation enables protease-independent tumor-cell invasion in vivo. Curr Biol 2006;16:1515-1523
23. Zaman MH, Trapani LM, Sieminski AL, et al. Migration of tumor cells in 3D matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis. Proc Natl Acad Sci USA 2006;103: 10889-10894
24. Ulrich TA, de Juan Pardo EM, Kumar S. The mechanical rigidity of the extracellular matrix regulates the structure, motility, and proliferation of glioma cells. Cancer Res 2009;69:4167-4174
25. Ridley AJ, Paterson HF, Johnston CL, et al. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 1992;70:401-410
26. Ridley AJ, Hall A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 1992;70:389-399
27. Nobes CD, Hall A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 1995;81:53-62
28. Miki H, Suetsugu S, Takenawa T. WAVE, a novel WASP-family protein involved in actin reorganization induced by Rac. EMBO J 1998;17: 6932-6941
29. Rohatgi R, Ma L, Miki H, et al. The interaction between N-WASP and the Arp2/3 complex links Cdc42-dependent signals to actin assembly. Cell 1999;97:221-231
30. Ridley AJ. Rho GTPases and cell migration. J Cell Sci 2001;114(Pt 15): 2713-2722
31. Chou J, Burke NA, Iwabu A, et al. Directional motility induced by epidermal growth factor requires Cdc42. Exp Cell Res 2003;287: 47-56
32. Wilkinson S, Paterson HF, Marshall CJ. Cdc42-MRCK and Rho-ROCK signalling cooperate in myosin phosphorylation and cell invasion. Nat Cell Biol 2005;7:255-261
33. Keller H, Eggli P. Protrusive activity, cytoplasmic compartmentalization, and restriction rings in locomoting blebbing Walker carcinosarcoma cells are related to detachment of cortical actin from the plasma membrane. Cell Motil Cytoskeleton 1998;41:181-193
34. Charras GT, Hu CK, Coughlin M, et al. Reassembly of contractile actin cortex in cell blebs. J Cell Biol 2006;175:477-490
35. Sanz-Moreno V, Gadea G, Ahn J, et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell 2008;135:510-523
36. Yamazaki D, Kurisu S, Takenawa T. Involvement of Rac and Rho signaling in cancer cell motility in 3D substrates. Oncogene 2009;28: 1570-1583
37. Bornstein P, Sage EH. Matricellular proteins: Extracellular modulators of cell function. Curr Opin Cell Biol 2002;14:608-616
38. Maquart FX, Simeon A, Pasco S, et al. Regulation of cell activity by the extracellular matrix: The concept of matrikines. J Soc Biol 1999; 193:423-428
39. Davis GE, Bayless KJ, Davis MJ, et al. Regulation of tissue injury responses by the exposure of matricryptic sites within extracellular matrix molecules. Am J Pathol 2000;156:1489-1498
40. DiMilla PA, Stone JA, Quinn JA, et al. Maximal migration of human smooth muscle cells on fibronectin and type IV collagen occurs at an intermediate attachment strength. J Cell Biol 1993;122:729-737
41. DiMilla PA, Barbee K, Lauffenburger DA. Mathematical model for the effects of adhesion and mechanics on cell migration speed. Biophys J 1991;60:15-37
42. Palecek SP, Loftus JC, Ginsberg MH, et al. Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature 1997;385:537-540
43. Ware MF, Wells A, Lauffenburger DA. Epidermal growth factor alters fibroblast migration speed and directional persistence reciprocally and in a matrix-dependent manner. J Cell Sci 1998;111(Pt 16):2423-2432
44. Xie H, Pallero MA, Gupta K, et al. EGF receptor regulation of cell motility: EGF induces disassembly of focal adhesions independently of the motility-Associated PLCgamma signaling pathway. J Cell Sci 1998;111(Pt 5):615-624
45. Jones FS, Jones PL. The tenascin family of ECM glycoproteins: Structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 2000;218:235-259
46. Pas J, Wyszko E, Rolle K, et al. Analysis of structure and function of tenascin-C. Int J Biochem Cell Biol 2006;38:1594-1602
47. Aukhil I, Joshi P, Yan Y, et al. Cell- and heparin-binding domains of the hexabrachion arm identified by tenascin expression proteins. J Biol Chem 1993;268:2542-2553
48. Chiquet-Ehrismann R, Chiquet M. Tenascins: Regulation and putative functions during pathological stress. J Pathol 2003;200:488-499
49. Orend G. Potential oncogenic action of tenascin-C in tumorigenesis. Int J Biochem Cell Biol 2005;37:1066-1083
50. Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett 2006;244:143-163
51. Erickson HP, Bourdon MA. Tenascin: An extracellular matrix protein prominent in specialized embryonic tissues and tumors. Annu Rev Cell Biol 1989;5:71-92
52. Midwood KS, Orend G. The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal 2009;3:287-310
53. Prieto AL, Andersson-Fisone C, Crossin KL. Characterization of multiple adhesive and counteradhesive domains in the extracellular matrix protein cytotactin. J Cell Biol 1992;119:663-678
54. Spring J, Beck K, Chiquet-Ehrismann R. Two contrary functions of tenascin: Dissection of the active sites by recombinant tenascin fragments. Cell 1989;59:325-334
55. Hancox RA, Allen MD, Holliday DL, et al. Tumour-Associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res 2009;11:R24
56. Tremble P, Chiquet-Ehrismann R, Werb Z. The extracellular matrix ligands fibronectin and tenascin collaborate in regulating collagenase gene expression in fibroblasts. Mol Biol Cell 1994;5: 439-453
57. Dang D, Yang Y, Li X, et al. Matrix metalloproteinases and TGFbeta1 modulate oral tumor cell matrix. Biochem Biophys Res Commun 2004;316:937-942
58. Siri A, Knauper V, Veirana N, et al. Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem 1995;270:8650-8654
59. Wenk MB, Midwood KS, Schwarzbauer JE. Tenascin-C suppresses Rho activation. J Cell Biol 2000;150:913-920
60. Sanz-Moreno V, Gaggioli C, Yeo M, et al. ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell 2011;20:229-245
61. Yamaguchi H. Pathological roles of invadopodia in cancer invasion and metastasis. Eur J Cell Biol 2012;91:902-907
62. Beck K, Hunter I, Engel J. Structure and function of laminin: Anatomy of a multidomain glycoprotein. FASEB J 1990;4:148-160
63. Jones PL, Jones FS. Tenascin-C in development and disease: Gene regulation and cell function. Matrix Biol 2000;19:581-596
64. Tsuruta D, Kobayashi H, Imanishi H, et al. Laminin-332-integrin interaction: A target for cancer therapy?. Curr Med Chem 2008;15: 1968-1975
65. Koshikawa N, Giannelli G, Cirulli V, et al. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol 2000;148:615-624
66. Giannelli G, Falk-Marzillier J, Schiraldi O, et al. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997;277:225-228
67. Shang M, Koshikawa N, Schenk S, et al. The LG3 module of laminin-5 harbors a binding site for integrin alpha3beta1 that promotes cell adhesion, spreading, and migration. J Biol Chem 2001;276: 33045-33053
68. Choma DP, Milano V, Pumiglia KM, et al. Integrin alpha3beta1-dependent activation of FAK/Src regulates Rac1-mediated keratinocyte polarization on laminin-5. J Invest Dermatol 2007;127:31-40
69. Guess CM, Quaranta V. Defining the role of laminin-332 in carcinoma. Matrix Biol 2009;28:445-455
70. Pyke C, Romer J, Kallunki P, et al. The gamma 2 chain of kalinin/ laminin 5 is preferentially expressed in invading malignant cells in human cancers. Am J Pathol 1994;145:782-791
71. Gagnoux-Palacios L, Allegra M, Spirito F, et al. The short arm of the laminin gamma2 chain plays a pivotal role in the incorporation of laminin 5 into the extracellular matrix and in cell adhesion. J Cell Biol 2001;153:835-850
72. Cheng CY, Sun CC, Yu WH, et al. Novel laminin 5 gamma 2-chain fragments potentiating the limbal epithelial cell outgrowth on amniotic membrane. Invest Ophthalmol Vis Sci 2009;50:4631-4639
73. D'Alessio S, Gerasi L, Blasi F. uPAR-deficient mouse keratinocytes fail to produce EGFR-dependent laminin-5, affecting migration in vivo and in vitro. J Cell Sci 2008;121(Pt 23):3922-3932
74. Pyke C, Salo S, Ralfkiaer E, et al. Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res 1995;55:4132-4139
75. Lindberg P, Larsson A, Nielsen BS. Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin gamma-2 chain is an early coordinated event in incipient oral squamous cell carcinoma. Int J Cancer 2006;118:2948-2956
76. Mamoune A, Kassis J, Kharait S, et al. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling. Exp Cell Res 2004;299:91-100
77. Gout SP, Jacquier-Sarlin MR, Rouard-Talbot L, et al. RhoA-dependent switch between alpha2beta1 and alpha3beta1 integrins is induced by laminin-5 during early stage of HT-29 cell differentiation. Mol Biol Cell 2001;12:3268-3281
78. Zhou H, Kramer RH. Integrin engagement differentially modulates epithelial cell motility by RhoA/ROCK and PAK1. J Biol Chem 2005;280:10624-10635
79. Nguyen BP, Ren XD, Schwartz MA, et al. Ligation of integrin alpha 3beta 1 by laminin 5 at the wound edge activates Rho-dependent adhesion of leading keratinocytes on collagen. J Biol Chem 2001;276: 43860-43870
80. Maurer P, Mayer U, Bruch M, et al. High-Affinity and low-Affinity calcium binding and stability of the multidomain extracellular 40-kDa basement membrane glycoprotein (BM-40/SPARC/osteonectin). Eur J Biochem 1992;205:233-240
81. Lane TF, Sage EH. The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J 1994;8:163-173
82. Hohenester E, Maurer P, Timpl R. Crystal structure of a pair of follistatin-like and EF-hand calcium-binding domains in BM-40. EMBO J 1997;16:3778-3786
83. Weaver MS, Workman G, Sage EH. The copper binding domain of SPARC mediates cell survival in vitro via interaction with integrin beta1 and activation of integrin-linked kinase. J Biol Chem 2008;283: 22826-22837
84. Pavasant P, Yongchaitrakul T. Secreted protein acidic, rich in cysteine induces pulp cell migration via alphavbeta3 integrin and extracellular signal-regulated kinase. Oral Dis 2008;14:335-340
85. De S, Chen J, Narizhneva NV, et al. Molecular pathway for cancer metastasis to bone. J Biol Chem 2003;278:39044-39050
86. Arnold SA, Brekken RA. SPARC: A matricellular regulator of tumorigenesis. J Cell Commun Signal 2009;3:255-273
87. Chlenski A, Cohn SL. Modulation of matrix remodeling by SPARC in neoplastic progression. Semin Cell Dev Biol 2010;21:55-65
88. Sage H, Vernon RB, Funk SE, et al. SPARC, a secreted protein associated with cellular proliferation, inhibits cell spreading in vitro and exhibits Ca+2-dependent binding to the extracellular matrix. J Cell Biol 1989;109:341-356
89. Murphy-Ullrich JE, Lane TF, Pallero MA, et al. SPARC mediates focal adhesion disassembly in endothelial cells through a follistatin-like region and the Ca(2+)-binding EF-hand. J Cell Biochem 1995;57: 341-350
90. McClung HM, Golembieski WA, Schultz CR, et al. Deletion of the SPARC acidic domain or EGF-like module reduces SPARC-induced migration and signaling through p38 MAPK/HSP27 in glioma. Carcinogenesis 2012;33:275-284
91. Barker TH, Baneyx G, Cardo-Vila M, et al. SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity. J Biol Chem 2005;280:36483-36493
92. Tremble PM, Lane TF, Sage EH, et al. SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. J Cell Biol 1993;121: 1433-1444
93. Kunigal S, Gondi CS, Gujrati M, et al. SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA. Int J Oncol 2006;29:1349-1357
94. Kupprion C, Motamed K, Sage EH. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J Biol Chem 1998;273:29635-29640
95. Raines EW, Lane TF, Iruela-Arispe ML, et al. The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc Natl Acad Sci USA 1992;89:1281-1285
96. Bhoopathi P, Gondi CS, Gujrati M, et al. SPARC mediates Src-induced disruption of actin cytoskeleton via inactivation of small GTPases Rho-Rac-Cdc42. Cell Signal 2011;23:1978-1987
97. Said N, Najwer I, Motamed K. Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer. Am J Pathol 2007;170:1054-1063
98. Lane TF, Iruela-Arispe ML, Sage EH. Regulation of gene expression by SPARC during angiogenesis in vitro. Changes in fibronectin, thrombospondin-1, and plasminogen activator inhibitor-1. J Biol Chem 1992;267:16736-16745
99. Bornstein P. Thrombospondins: Structure and regulation of expression. FASEB J 1992;6:3290-3299
100. Liu A, Mosher DF, Murphy-Ullrich JE, et al. The counteradhesive proteins, thrombospondin 1 and SPARC/osteonectin, open the tyrosine phosphorylation- responsive paracellular pathway in pulmonary vascular endothelia. Microvasc Res 2009;77:13-20
101. Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: Mechanisms and physiology. Cytokine Growth Factor Rev 2000;11:59-69
102. Adams JC, Kureishy N, Taylor AL. A role for syndecan-1 in coupling fascin spike formation by thrombospondin-1. J Cell Biol 2001;152: 1169-1182
103. Nunes SS, Outeiro-Bernstein MA, Juliano L, et al. Syndecan-4 contributes to endothelial tubulogenesis through interactions with two motifs inside the pro-Angiogenic N-Terminal domain of thrombospondin-1. J Cell Physiol 2008;214:828-837
104. Calzada MJ, Annis DS, Zeng B, et al. Identification of novel beta1 integrin binding sites in the type 1 and type 2 repeats of thrombospondin-1. J Biol Chem 2004;279:41734-41743
105. Staniszewska I, Zaveri S, Del Valle L, et al. Interaction of alpha9beta1 integrin with thrombospondin-1 promotes angiogenesis. Circ Res 2007;100:1308-1316
106. Gao AG, Lindberg FP, Dimitry JM, et al. Thrombospondin modulates alpha v beta 3 function through integrin-Associated protein. J Cell Biol 1996;135:533-544
107. Gao AG, Lindberg FP, Finn MB, et al. Integrin-Associated protein is a receptor for the C-Terminal domain of thrombospondin. J Biol Chem 1996;271:21-24
108. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressordependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990;87:6624-6628
109. Isenberg JS, Martin-Manso G, Maxhimer JB, et al. Regulation of nitric oxide signalling by thrombospondin 1: Implications for antiangiogenic therapies. Nat Rev Cancer 2009;9:182-194
110. Fontana A, Filleur S, Guglielmi J, et al. Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo. Int J Cancer 2005;116:686-691
111. Filleur S, Volpert OV, Degeorges A, et al. In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. Genes Dev 2001;15:1373-1382
112. Lin XD, Chen SQ, Qi YL, et al. Overexpression of thrombospondin-1 in stromal myofibroblasts is associated with tumor growth and nodal metastasis in gastric carcinoma. J Surg Oncol 2012;106:94-100
113. Nucera C, Porrello A, Antonello ZA, et al. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci USA 2010;107:10649-10654
114. Roberts DD. Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J 1996;10:1183-1191
115. Bein K, Simons M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem 2000;275:32167-32173
116. Albo D, Shinohara T, Tuszynski GP. Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer. J Surg Res 2002;108:51-60
117. Murphy-Ullrich JE, Hook M. Thrombospondin modulates focal adhesions in endothelial cells. J Cell Biol 1989;109:1309-1319
118. Murphy-Ullrich JE, Gurusiddappa S, Frazier WA, et al. Heparin-binding peptides from thrombospondins 1 and 2 contain focal adhesionlabilizing activity. J Biol Chem 1993;268:26784-26789
119. Orr AW, Pallero MA, Xiong WC, et al. Thrombospondin induces RhoA inactivation through FAK-dependent signaling to stimulate focal adhesion disassembly. J Biol Chem 2004;279:48983-48992
120. Orr AW, Elzie CA, Kucik DF, et al. Thrombospondin signaling through the calreticulin/LDL receptor-related protein co-complex stimulates random and directed cell migration. J Cell Sci 2003;116(Pt 14): 2917-2927
121. Arnoletti JP, Albo D, Granick MS, et al. Thrombospondin and transforming growth factor-beta 1 increase expression of urokinasetype plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells. Cancer 1995;76: 998-1005
122. Albo D, Arnoletti JP, Castiglioni A, et al. Thrombospondin (TSP) and transforming growth factor beta 1 (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 (PAI-1) production and stimulate tumor cell attachment in vitro. Biochem Biophys Res Commun 1994;203:857-865
123. Cartier-Michaud A, Malo M, Charriere-Bertrand C, et al. Matrix-bound PAI-1 supports cell blebbing via RhoA/ROCK1 signaling. PLoS One 2012;7:e32204
124. Albo D, Berger DH, Wang TN, et al. Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system. Surgery 1997;122:493-499, discussion 9-500
125. Albo D, Rothman VL, Roberts DD, et al. Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor. Br J Cancer 2000;83:298-306
126. Bornstein P, Armstrong LC, Hankenson KD, et al. Thrombospondin 2, a matricellular protein with diverse functions. Matrix Biol 2000; 19:557-568
127. Krady MM, Zeng J, Yu J, et al. Thrombospondin-2 modulates extracellular matrix remodeling during physiological angiogenesis. Am J Pathol 2008;173:879-891
128. Angelucci A, Festuccia C, Gravina GL, et al. Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cells. Prostate 2004;59:157-166
129. Tuck AB, Hota C, Wilson SM, et al. Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene 2003;22: 1198-1205
130. Timpl R, Sasaki T, Kostka G, et al. Fibulins: A versatile family of extracellular matrix proteins. Nat Rev Mol Cell Biol 2003;4:479-489
131. Giltay R, Timpl R, Kostka G. Sequence, recombinant expression and tissue localization of two novel extracellular matrix proteins, fibulin-3 and fibulin-4. Matrix Biol 1999;18:469-480
132. Gallagher WM, Currid CA, Whelan LC. Fibulins and cancer: Friend or foe?. Trends Mol Med 2005;11:336-340
133. de Vega S, Iwamoto T, Yamada Y. Fibulins: Multiple roles in matrix structures and tissue functions. Cell Mol Life Sci 2009;66:;1890-1902
134. Obaya AJ, Rua S, Moncada-Pazos A, et al. The dual role of fibulins in tumorigenesis. Cancer Lett 2012;325:132-138
135. Camaj P, Seeliger H, Ischenko I, et al. EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells. Biol Chem 2009;390:1293-1302
136. Yates CC, Bodnar R, Wells A. Matrix control of scarring. Cell Mol Life Sci 2011;68:1871-1881
137. Wells A, Chao YL, Grahovac J, et al. Epithelial and mesenchymal phenotypic switchings modulate cell motility in metastasis. Front Biosci 2011;16:815-837
138. Wolf K, Alexander S, Schacht V, et al. Collagen-based cell migration models in vitro and in vivo. Semin Cell Dev Biol 2009;20:931-941
139. Ilina O, Bakker GJ, Vasaturo A, et al. Two-photon laser-generated microtracks in 3D collagen lattices: Principles of MMP-dependent and -independent collective cancer cell invasion. Phys Biol 2011;8: 015010
140. Gritsenko PG, Ilina O, Friedl P. Interstitial guidance of cancer invasion. J Pathol 2012;226:185-199
141. Merline R, Schaefer RM, Schaefer L. The matricellular functions of small leucine-rich proteoglycans (SLRPs). J Cell Commun Signal 2009;3:323-335
142. Chopra RK, Pearson CH, Pringle GA, et al. Dermatan sulphate is located on serine-4 of bovine skin proteodermatan sulphate. Demonstration that most molecules possess only one glycosaminowww. glycan chain and comparison of amino acid sequences around glycosylation sites in different proteoglycans. Biochem J 1985;232: 277-279
143. Bianco P, Fisher LW, Young MF, et al. Expression and localization of the two small proteoglycans biglycan and decorin in developing human skeletal and non-skeletal tissues. J Histochem Cytochem 1990;38:1549-1563
144. Keene DR, San Antonio JD, Mayne R, et al. Decorin binds near the C terminus of type I collagen. J Biol Chem 2000;275:21801-21804
145. Danielson KG, Baribault H, Holmes DF, et al. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol 1997;136:729-743
146. Zhang G, Ezura Y, Chervoneva I, et al. Decorin regulates assembly of collagen fibrils and acquisition of biomechanical properties during tendon development. J Cell Biochem 2006;98:1436-1449
147. Iozzo RV, Moscatello DK, McQuillan DJ, et al. Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem 1999;274:4489-4492
148. Goldoni S, Humphries A, Nystrom A, et al. Decorin is a novel antagonistic ligand of the Met receptor. J Cell Biol 2009;185: 743-754
149. Merline R, Moreth K, Beckmann J, et al. Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21. Sci Signal 2011;4:ra75
150. Iozzo RV, Buraschi S, Genua M, et al. Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling. J Biol Chem 2011;286:34712-34721
151. Hildebrand A, Romaris M, Rasmussen LM, et al. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J 1994;302(Pt 2): 527-534
152. Bi X, Pohl NM, Qian Z, et al. Decorin-mediated inhibition of colorectal cancer growth and migration is associated with E-cadherin in vitro and in mice. Carcinogenesis 2012;33:326-330
153. Mauviel A, Santra M, Chen YQ, et al. Transcriptional regulation of decorin gene expression. Induction by quiescence and repression by tumor necrosis factor-Alpha. J Biol Chem 1995;270:11692-11700
154. Sofeu Feugaing DD, Gotte M, Viola M. More than matrix: The multifaceted role of decorin in cancer. Eur J Cell Biol 2013;92:1-11
155. Franz M, Hansen T, Richter P, et al. Complex formation of the laminin-5 gamma2 chain and large unspliced tenascin-C in oral squamous cell carcinoma in vitro and in situ: Implications for sequential modulation of extracellular matrix in the invasive tumor front. Histochem Cell Biol 2006;126:125-131
156. Berndt A, Borsi L, Hyckel P, et al. Fibrillary co-deposition of laminin-5 and large unspliced tenascin-C in the invasive front of oral squamous cell carcinoma in vivo and in vitro. J Cancer Res Clin Oncol 2001;127:286-292.